Meeting
2020 ASCO Virtual Scientific Program
An FDA analysis of the association of tumor growth rate and overall and progression-free survival in metastatic non-small cell lung cancer (NSCLC) patients.
Authors
Yutao Gong
U.S. Food and Drug Administration, Silver Spring, MD
Yutao Gong , Jeremy Mason , Yuan-Li Shen , Elaine Chang , Dickran Kazandjian , Gideon Michael Blumenthal , Harpreet Singh , Marc Robert Theoret , Shenghui Tang , Richard Pazdur , Julia A. Beaver
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Biologic Correlates
Citation
J Clin Oncol 38: 2020 (suppl; abstr 9541)
DOI
10.1200/JCO.2020.38.15_suppl.9541
Abstract #
9541
Poster Bd #
307
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Real-world effectiveness of immune checkpoint inhibitors alone or in combination with chemotherapy in metastatic non–small cell lung cancer.
First Author: Lingzhi Hong
Poster
2023 ASCO Annual Meeting
Treatment at twilight: Is less more in the management of octogenarians with non-small cell lung cancer (NSCLC)?
First Author: Ethan Burns
Poster
2021 ASCO Annual Meeting
The role of chemotherapy plus immune checkpoint inhibitors in oncogenic driven non-small cell lung cancer: A University of California Lung Cancer Consortium retrospective study.
First Author: Karen Kelly
Poster
2021 ASCO Annual Meeting
Optimal next-generation sequencing (NGS) panel for estimating tumor mutation burden (TMB) and its clinical implication for non-small cell lung cancer (NSCLC).
First Author: Takaya Ikeda